ProQR Therapeutics N.V. (PRQR) Stock Analysis & Winston Score

ProQR Therapeutics is a Dutch biotechnology company that develops RNA-based medicines for rare genetic eye diseases. Its main focus is on inherited retinal dystrophies — conditions where people slowly lose their vision because of a genetic mutation. The company's lead programs target diseases like Leber congenital amaurosis and Usher syndrome, which affect a small number of patients worldwide. ProQR makes money by advancing experimental drugs through clinical trials, with the goal of eventually selling approved treatments or licensing them to larger pharmaceutical partners. The company is headquartered in Leiden, the Netherlands, and operates primarily in Europe and the United States. Its high gross margin reflects the early-stage nature of its revenue, which comes mainly from grants and collaborations rather than product sales. The biggest risk is that clinical trials are expensive and often fail — ProQR is spending far more than it earns, and it will need to raise additional capital or secure a major partnership to fund its pipeline long-term.